Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00195663




Registration number
NCT00195663
Ethics application status
Date submitted
13/09/2005
Date registered
20/09/2005
Date last updated
12/07/2013

Titles & IDs
Public title
Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis
Scientific title
A Prospective Multi-Centre Randomised, Double-Blind, Active Comparator-Controlled, Parallel-Groups Study Comparing the Fully Human Monoclonal Anti-TNFa Antibody Adalimumab Given Every Second Week With Methotrexate Given Weekly and the Combination of Adalimumab and Methotrexate Administered Over 2 Years in Patients With Early Rheumatoid Arthritis (PREMIER).
Secondary ID [1] 0 0
DE013
Universal Trial Number (UTN)
Trial acronym
PREMIER
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Early Rheumatoid Arthritis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental: Adalimumab - Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase and then adalimumab 40 mg every other week for up to 8 years in the open-label extension.

Experimental: Adalimumab + methotrexate - Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.

Experimental: Methotrexate - Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 52
Timepoint [1] 0 0
Baseline and 52 Weeks
Primary outcome [2] 0 0
Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52
Timepoint [2] 0 0
Baseline and Week 52
Secondary outcome [1] 0 0
Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52
Timepoint [1] 0 0
Baseline and Week 52
Secondary outcome [2] 0 0
Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 104
Timepoint [2] 0 0
Baseline and Week 104
Secondary outcome [3] 0 0
Change From Baseline in Modified Total Sharp Score (mTSS) at Week 104
Timepoint [3] 0 0
Baseline and Week 104
Secondary outcome [4] 0 0
Number of Participants Who Achieved Clinical Remission, Defined as a Disease Activity 28 (DAS28) Score < 2.6 at Week 52
Timepoint [4] 0 0
Week 52
Secondary outcome [5] 0 0
Change From Baseline in the Physical Component of the Short Form-36 Health Status Survey (SF-36) at Week 52
Timepoint [5] 0 0
Baseline and Week 52
Secondary outcome [6] 0 0
Number of Participants With Major Clinical Response After 104 Weeks of Treatment
Timepoint [6] 0 0
Any 6 continuous months from Baseline to Week 104
Secondary outcome [7] 0 0
Change From Baseline in the Mental Component of the Short Form-36 Health Status Survey (SF-36) at Week 52
Timepoint [7] 0 0
Baseline and Week 52
Secondary outcome [8] 0 0
Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Weeks 26 and 76
Timepoint [8] 0 0
Baseline and Weeks 26 and 76
Secondary outcome [9] 0 0
Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria During the Double-blind Phase
Timepoint [9] 0 0
Baseline and Weeks 26, 52, 76, and 104
Secondary outcome [10] 0 0
Number of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria During the Double-blind Phase
Timepoint [10] 0 0
Baseline and Weeks 26, 52, 76, and 104
Secondary outcome [11] 0 0
Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) During the Double-blind Treatment Phase
Timepoint [11] 0 0
Baseline and Weeks 12, 26, 76, and 104
Secondary outcome [12] 0 0
Number of Participants With Improvement in the HAQ-DI Score = 0.3 During the Double-blind Treatment Phase
Timepoint [12] 0 0
Baseline and Weeks 26, 52, 76, and 104
Secondary outcome [13] 0 0
Change From Baseline in Health Utilities Index Mark 2 and Mark 3 (HUI 2/3) During the Double-blind Treatment Phase
Timepoint [13] 0 0
Baseline and Weeks 26, 52, and 104
Secondary outcome [14] 0 0
Change From Baseline in the Short Form-36 Health Status Survey (SF-36) During the Double-blind Treatment Phase
Timepoint [14] 0 0
Baseline and Weeks 26 and 104
Secondary outcome [15] 0 0
Numeric American College of Rheumatology (ACR-N) During the Double-blind Treatment Phase
Timepoint [15] 0 0
Baseline and Weeks 26, 52, 76, and 104
Secondary outcome [16] 0 0
Change From Baseline in Disease Activity Score (DAS28) During the Double-blind Treatment Phase
Timepoint [16] 0 0
Baseline and Weeks 26, 52, 76, and 104
Secondary outcome [17] 0 0
Change From Baseline in Joint Erosion Score During the Double-blind Treatment Period
Timepoint [17] 0 0
Baseline and Weeks 52 and 104
Secondary outcome [18] 0 0
Change From Baseline in Joint Space Narrowing Score During the Double-blind Treatment Period
Timepoint [18] 0 0
Baseline and Weeks 52 and 104
Secondary outcome [19] 0 0
Number of Participants With No Worsening in Modified Total Sharp Score or Components During the Double-blind Treatment Phase
Timepoint [19] 0 0
Baseline and Weeks 52 and 104
Secondary outcome [20] 0 0
Number of Participants With No Erosions at Baseline and No New Erosions at Weeks 52 and 104
Timepoint [20] 0 0
Baseline and Weeks 52 and 104
Secondary outcome [21] 0 0
Number of Participants With Non-Involved Joints at Baseline and No Newly Involved Joints at Weeks 52 and 104
Timepoint [21] 0 0
Baseline and Weeks 52 and 104
Secondary outcome [22] 0 0
Number of Participants Meeting ACR20 Response Criteria Over 10 Years by Adalimumab Exposure
Timepoint [22] 0 0
Baseline and after 1, 2, 5, and 10 years of adalimumab exposure. Baseline was the last value prior to the first dose of adalimumab.
Secondary outcome [23] 0 0
Number of Participants Meeting ACR50 Response Criteria Over 10 Years by Adalimumab Exposure
Timepoint [23] 0 0
Baseline and after 1, 2, 5, and 10 years of adalimumab exposure. Baseline was the last value prior to the first dose of adalimumab.
Secondary outcome [24] 0 0
Number of Participants Meeting ACR70 Response Criteria Over 10 Years by Adalimumab Exposure
Timepoint [24] 0 0
Baseline and after 1, 2, 5, and 10 years of adalimumab exposure. Baseline was the last value prior to the first dose of adalimumab.
Secondary outcome [25] 0 0
Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) Over 10 Years by Adalimumab Exposure
Timepoint [25] 0 0
Baseline and Years 1, 2, 5, and 10. Baseline was the last value prior to the first dose of adalimumab. For patients randomized to the MTX arm in the DB phase, Baseline was the last visit prior to the first adalimumab dose at Week 106.
Secondary outcome [26] 0 0
Change From Baseline in DAS28 Over 10 Years by Adalimumab Exposure
Timepoint [26] 0 0
Baseline and Years 1, 2, 5, and 10. Baseline was the last value prior to the first dose of adalimumab. For patients randomized to the MTX arm in the DB phase, Baseline was the last visit prior to the first adalimumab dose at Week 106.
Secondary outcome [27] 0 0
Number of Participants With DAS28 < 2.6 and < 3.2 Over 10 Years by Adalimumab Exposure
Timepoint [27] 0 0
After 1, 2, 5, and 10 years of adalimumab exposure
Secondary outcome [28] 0 0
Change From Baseline in Modified Total Sharp Score (mTSS) Over 10 Years
Timepoint [28] 0 0
Baseline (prior to first study drug treatment) and Years 2 and 10
Secondary outcome [29] 0 0
Number of Participants With No Radiographic Progression Over 10 Years
Timepoint [29] 0 0
Baseline (prior to first study drug treatment) and Years 2 and 10.
Secondary outcome [30] 0 0
Composite Score of ACR50 Plus No Change in Modified Total Sharp Score
Timepoint [30] 0 0
Year 10
Secondary outcome [31] 0 0
Number of Participants With a Major Clinical Response Over 10 Years by Adalimumab Exposure
Timepoint [31] 0 0
From the first dose of adalimumab (at Week 1 or Week 106 for patients initially randomized to methotrexate in the DB phase) to Year 10
Secondary outcome [32] 0 0
Number of Participants With Improvement in HAQ-DI by 0.22 and 0.5 Units Over 10 Years by Adalimumab Exposure
Timepoint [32] 0 0
Baseline and Years 1, 2, 5, and 10. Baseline was the last value prior to the first dose of adalimumab. For patients randomized to the MTX arm in the DB phase, Baseline was the last visit prior to the first adalimumab dose at Week 106.

Eligibility
Key inclusion criteria
* Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.
* Diagnosis of rheumatoid arthritis (RA) as defined by the 1987-revised American College of Rheumatology (ACR) criteria, with a disease duration less than 3 years, at least 8 swollen joints out of the 66 joints assessed, at least 10 tender joints out of the 68 joints assessed, at least 1 joint erosion or rheumatoid factor (RF) positivity, erythrocyte sedimentation rate (ESR) >= 28 mm/1h or C-reactive protein (CRP) >= 1.5 mg/dl
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Chronic arthritis diagnosed before the age of 16
* Preceding treatment with MTX, cyclophosphamide, cyclosporin, azathioprine or more than 2 other disease-modifying anti-rheumatic drugs (DMARDs)
* Subject previously received anti-tumor necrosis factor (TNF) therapy
* Permanently wheelchair-bound or bedridden patients
* Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study
* Female subject who is pregnant or breast-feeding or considering becoming pregnant

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/12/2000
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/04/2012
Sample size
Target
Accrual to date
Final
799
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Site Reference ID/Investigator# 310 - Brisbane
Recruitment hospital [2] 0 0
Site Reference ID/Investigator# 755 - Camperdown
Recruitment hospital [3] 0 0
Site Reference ID/Investigator# 337 - Clayton
Recruitment hospital [4] 0 0
Site Reference ID/Investigator# 331 - Darlinghurst, Sydney
Recruitment hospital [5] 0 0
Site Reference ID/Investigator# 745 - Kogarah
Recruitment hospital [6] 0 0
Site Reference ID/Investigator# 738 - Maroochydore
Recruitment hospital [7] 0 0
Site Reference ID/Investigator# 335 - New Lambton
Recruitment hospital [8] 0 0
Site Reference ID/Investigator# 737 - Shenton Park
Recruitment hospital [9] 0 0
Site Reference ID/Investigator# 307 - South Hobart
Recruitment hospital [10] 0 0
Site Reference ID/Investigator# 427 - West Heidelberg
Recruitment hospital [11] 0 0
Site Reference ID/Investigator# 739 - Woodville
Recruitment postcode(s) [1] 0 0
4102 - Brisbane
Recruitment postcode(s) [2] 0 0
2050 - Camperdown
Recruitment postcode(s) [3] 0 0
3168 - Clayton
Recruitment postcode(s) [4] 0 0
2010 - Darlinghurst, Sydney
Recruitment postcode(s) [5] 0 0
2217 - Kogarah
Recruitment postcode(s) [6] 0 0
4558 - Maroochydore
Recruitment postcode(s) [7] 0 0
2305 - New Lambton
Recruitment postcode(s) [8] 0 0
6008 - Shenton Park
Recruitment postcode(s) [9] 0 0
7004 - South Hobart
Recruitment postcode(s) [10] 0 0
3081 - West Heidelberg
Recruitment postcode(s) [11] 0 0
5011 - Woodville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Nebraska
Country [9] 0 0
United States of America
State/province [9] 0 0
New Hampshire
Country [10] 0 0
United States of America
State/province [10] 0 0
North Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Oklahoma
Country [13] 0 0
United States of America
State/province [13] 0 0
Oregon
Country [14] 0 0
United States of America
State/province [14] 0 0
Pennsylvania
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
United States of America
State/province [16] 0 0
Washington
Country [17] 0 0
Austria
State/province [17] 0 0
Vienna
Country [18] 0 0
Belgium
State/province [18] 0 0
Brussels
Country [19] 0 0
Belgium
State/province [19] 0 0
Diepenbeek
Country [20] 0 0
Belgium
State/province [20] 0 0
Ghent
Country [21] 0 0
Belgium
State/province [21] 0 0
Leuven
Country [22] 0 0
Belgium
State/province [22] 0 0
Liege
Country [23] 0 0
Canada
State/province [23] 0 0
Ontario
Country [24] 0 0
Canada
State/province [24] 0 0
Edmonton
Country [25] 0 0
Canada
State/province [25] 0 0
Hamilton
Country [26] 0 0
Canada
State/province [26] 0 0
Montreal
Country [27] 0 0
Canada
State/province [27] 0 0
Newmarket
Country [28] 0 0
Canada
State/province [28] 0 0
Pointe-Claire
Country [29] 0 0
Canada
State/province [29] 0 0
Richmond
Country [30] 0 0
Canada
State/province [30] 0 0
St. John's
Country [31] 0 0
Canada
State/province [31] 0 0
Toronto
Country [32] 0 0
Canada
State/province [32] 0 0
Victoria
Country [33] 0 0
Canada
State/province [33] 0 0
Winnipeg
Country [34] 0 0
Czech Republic
State/province [34] 0 0
Hradec Kralove
Country [35] 0 0
Czech Republic
State/province [35] 0 0
Plzen
Country [36] 0 0
Czech Republic
State/province [36] 0 0
Prague 2
Country [37] 0 0
Denmark
State/province [37] 0 0
Grasten
Country [38] 0 0
Finland
State/province [38] 0 0
Heinola
Country [39] 0 0
Finland
State/province [39] 0 0
Helsinki
Country [40] 0 0
France
State/province [40] 0 0
Bobigny
Country [41] 0 0
France
State/province [41] 0 0
Montpellier Cedex 5
Country [42] 0 0
France
State/province [42] 0 0
Paris Cedex 14
Country [43] 0 0
France
State/province [43] 0 0
Pierre Benite
Country [44] 0 0
France
State/province [44] 0 0
Rennes
Country [45] 0 0
France
State/province [45] 0 0
Strasbourg, Cedex 1
Country [46] 0 0
Germany
State/province [46] 0 0
Berlin-Buch
Country [47] 0 0
Germany
State/province [47] 0 0
Berlin
Country [48] 0 0
Germany
State/province [48] 0 0
Erlangen
Country [49] 0 0
Germany
State/province [49] 0 0
Freiburg
Country [50] 0 0
Germany
State/province [50] 0 0
Goerlitz
Country [51] 0 0
Germany
State/province [51] 0 0
Leipzig
Country [52] 0 0
Germany
State/province [52] 0 0
Munich
Country [53] 0 0
Germany
State/province [53] 0 0
Ratingen
Country [54] 0 0
Germany
State/province [54] 0 0
Vogelsang-Gommern
Country [55] 0 0
Ireland
State/province [55] 0 0
Cork
Country [56] 0 0
Ireland
State/province [56] 0 0
Dublin 4
Country [57] 0 0
Italy
State/province [57] 0 0
Genoa
Country [58] 0 0
Italy
State/province [58] 0 0
Naples
Country [59] 0 0
Italy
State/province [59] 0 0
Udine
Country [60] 0 0
Italy
State/province [60] 0 0
Verona
Country [61] 0 0
Netherlands
State/province [61] 0 0
Groningen
Country [62] 0 0
Netherlands
State/province [62] 0 0
Leiden
Country [63] 0 0
Netherlands
State/province [63] 0 0
Maastricht
Country [64] 0 0
Netherlands
State/province [64] 0 0
Nijmegen
Country [65] 0 0
Norway
State/province [65] 0 0
Osla
Country [66] 0 0
Slovakia
State/province [66] 0 0
Piestany
Country [67] 0 0
Spain
State/province [67] 0 0
Alicante
Country [68] 0 0
Spain
State/province [68] 0 0
Barcelona
Country [69] 0 0
Spain
State/province [69] 0 0
Guadalajara
Country [70] 0 0
Spain
State/province [70] 0 0
Madrid
Country [71] 0 0
Spain
State/province [71] 0 0
Santiago de Compostela
Country [72] 0 0
Spain
State/province [72] 0 0
Sevilla
Country [73] 0 0
Sweden
State/province [73] 0 0
Stockholm
Country [74] 0 0
Sweden
State/province [74] 0 0
Umea
Country [75] 0 0
Sweden
State/province [75] 0 0
Uppsala
Country [76] 0 0
Sweden
State/province [76] 0 0
Vasteras
Country [77] 0 0
Switzerland
State/province [77] 0 0
Lausanne
Country [78] 0 0
United Kingdom
State/province [78] 0 0
Bangor
Country [79] 0 0
United Kingdom
State/province [79] 0 0
Cambridge
Country [80] 0 0
United Kingdom
State/province [80] 0 0
Hereford
Country [81] 0 0
United Kingdom
State/province [81] 0 0
Leeds
Country [82] 0 0
United Kingdom
State/province [82] 0 0
London
Country [83] 0 0
United Kingdom
State/province [83] 0 0
Newcastle upon Tyne

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AbbVie (prior sponsor, Abbott)
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of the study is to assess the safety and efficacy of adalimumab in combination with methotrexate in patients with recent onset rheumatoid arthritis (RA), and to assess the long-term safety and maintenance of efficacy after treatment with adalimumab for up to 10 years.
Trial website
https://clinicaltrials.gov/study/NCT00195663
Trial related presentations / publications
Smolen J, Fleischmann R, Aletaha D, Li Y, Zhou Y, Sainsbury I, Galindo IL. Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials. Arthritis Res Ther. 2019 Nov 10;21(1):231. doi: 10.1186/s13075-019-2005-9.
Smolen JS, van Vollenhoven RF, Florentinus S, Chen S, Suboticki JL, Kavanaugh A. Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate. Ann Rheum Dis. 2018 Nov;77(11):1566-1572. doi: 10.1136/annrheumdis-2018-213502. Epub 2018 Aug 3.
Keystone EC, Breedveld FC, Kupper H, Li Y, Florentinus S, Sainsbury I. Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis. RMD Open. 2018 Jun 13;4(1):e000637. doi: 10.1136/rmdopen-2017-000637. eCollection 2018.
Keystone EC, Breedveld FC, van der Heijde D, van Vollenhoven RF, Emery P, Smolen JS, Sainsbury I, Florentinus S, Kupper H, Chen K, Kavanaugh A. Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. RMD Open. 2017 Sep 26;3(2):e000445. doi: 10.1136/rmdopen-2017-000445. eCollection 2017.
Moller B, Everts-Graber J, Florentinus S, Li Y, Kupper H, Finckh A. Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase III Trial. Arthritis Care Res (Hoboken). 2018 Jun;70(6):861-868. doi: 10.1002/acr.23427. Epub 2018 Apr 25.
Burmester GR, Landewe R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Feb;76(2):414-417. doi: 10.1136/annrheumdis-2016-209322. Epub 2016 Jun 23.
Landewe R, Smolen JS, Florentinus S, Chen S, Guerette B, van der Heijde D. Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis. Arthritis Res Ther. 2015 May 21;17(1):133. doi: 10.1186/s13075-015-0626-1.
Landewe R, Ostergaard M, Keystone EC, Florentinus S, Liu S, van der Heijde D. Analysis of integrated radiographic data from two long-term, open-label extension studies of adalimumab for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2015 Feb;67(2):180-6. doi: 10.1002/acr.22426.
Keystone EC, Haraoui B, Guerette B, Mozaffarian N, Liu S, Kavanaugh A. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study. J Rheumatol. 2014 Feb;41(2):235-43. doi: 10.3899/jrheum.121468. Epub 2013 Dec 1.
Keystone EC, Breedveld FC, van der Heijde D, Landewe R, Florentinus S, Arulmani U, Liu S, Kupper H, Kavanaugh A. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension. J Rheumatol. 2014 Jan;41(1):5-14. doi: 10.3899/jrheum.130543. Epub 2013 Nov 15.
Smolen JS, van der Heijde DM, Keystone EC, van Vollenhoven RF, Goldring MB, Guerette B, Cifaldi MA, Chen N, Liu S, Landewe RB. Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate. Ann Rheum Dis. 2013 Jul;72(7):1156-62. doi: 10.1136/annrheumdis-2012-201620. Epub 2012 Aug 22. Erratum In: Ann Rheum Dis. 2013 Aug;72(8):1432.
Strand V, Rentz AM, Cifaldi MA, Chen N, Roy S, Revicki D. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study. J Rheumatol. 2012 Jan;39(1):63-72. doi: 10.3899/jrheum.101161. Epub 2011 Nov 1.
Public notes

Contacts
Principal investigator
Name 0 0
Dawn Carlson
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00195663